Seeking Alpha

pwt750

pwt750
Send Message
View as an RSS Feed
View pwt750's Comments BY TICKER:
Latest  |  Highest rated
  • How Amarin Bulls Made The Right Choice [View article]
    seriously ? cafepharma for useful or factual opinions ? thats about 100:1 shot. That site features the worst of the worst (etc) for mis-represented and absurd claims. The only indicator one may access from CP is how sick, twisted and devious certain elements of society can be given an anonymous podium.
    Oct 13 10:51 AM | Likes Like |Link to Comment
  • Thumbs Down To Amarin's ANCHOR Would Sink Its Ship [View article]
    DECIMAL POINT FIXED !?!??! rawnoc, You USED the $12M in your calcs ! I see you also fixed that preposterous math fubar too that came along with that glaring error, but you don't suppose granting the company an extra HUNDRED TEN MILLION might sway analysis just a wee tad?

    shees.

    Other than 2~3 years of bank roll you MISSED TOTALLY, I must say "what an article ..."
    Oct 11 09:57 PM | 3 Likes Like |Link to Comment
  • Thumbs Down To Amarin's ANCHOR Would Sink Its Ship [View article]
    "Amarin Announces Completion of Offering of American Depositary Shares... resulting in net proceeds to Amarin of approximately $121.1 million"

    you call it 12.1 mill and run your math on it ? Wing it , much?

    Yeah I want to get my advice from you.
    Oct 11 08:03 PM | 5 Likes Like |Link to Comment
  • Drop The Anchor And Fish For Profits [View article]
    it was a term of the SPA agreement with FDA. Have REDUCE-IT 'substantially underway' in order to file the sNDA.
    em oh you ess eee
    Oct 9 05:54 PM | Likes Like |Link to Comment
  • A Stock That May Rally $20 In 3-Months [View instapost]
    "The FDA reviewed and approved Kalydeco in approximately three months under the agency’s priority review program that is designed to expedite the review of drugs. The priority review program uses a six-month review, instead of the standard 10 months, for drugs that may offer significant advances in treatment over available therapy.

    Kalydeco was approved ahead of the drug’s April 18, 2012 prescription user fee goal date and is designated as an orphan drug, which identifies the disease as affecting fewer than 200,000 people in the United States.

    Kalydeco is effective only in patients with CF who have the G551D mutation. It is not effective in CF patients with two copies of the F508 mutation in the CFTR gene, which is the most common mutation that results in CF. If a patient’s mutation status is not known, an FDA-cleared CF mutation test should be used to determine whether the G551D mutation is present.

    CF, which affects about 30,000 people in the United States, is the most common fatal genetic disease in the Caucasian population.

    About 4 percent of those with CF, or roughly 1,200 people, are believed to have the G551D mutation."
    Oct 7 03:14 AM | 1 Like Like |Link to Comment
  • JBI's Plastic2Oil Goes National [View article]
    the inside contact I know said they blew that deal, offering 12 tankers and finally sneaking in a fraction of that .. .late. Apparently caused US S some problems and that gate is locked now. Is this good ?
    Oct 4 10:53 AM | 1 Like Like |Link to Comment
  • JBI's Plastic2Oil Goes National [View article]
    Scam company. Terrible legal & performance history, even worse stock performance. IMO guaranteed loser. I'd prefer to invest under mattresses. Get out while you still can ( although 1000 share exchange is considered large for this name) so the trap is already set.
    Oct 4 10:49 AM | Likes Like |Link to Comment
  • AF Backtracking, AMRN Will Be Approved On Time [View instapost]
    I have seen a couple 100,000 shares or so dumped on the market mere minutes before one of your one sided hit pieces land on thestreet enough times to believe practically anything. But as I don't care for cats, carry on your extracurriculars.
    Sep 30 12:05 AM | Likes Like |Link to Comment
  • AF Backtracking, AMRN Will Be Approved On Time [View instapost]
    sts; regarding your brusque comment - perhaps punjabi does not RUN the clinic, he is apparently striving to enlighten (drag) the powers that be to the new paradigm (into the modern age) . Beyond that I presume you will get a first hand reply.
    Sep 28 08:15 PM | Likes Like |Link to Comment
  • AF Backtracking, AMRN Will Be Approved On Time [View instapost]
    af- as long as we are strolling down memory lane,
    I thank you for warning me off of those pre-data-selling data-mining venue-pickin no goods at ACAD. I thank me for not listening to you.

    Actually the parallels are even more striking. ACAD had lots of eggs thrown at it it while re-running a more insightful Pima. AMRN, while its re-running an improved JELIS. So predictable.
    Sep 26 11:31 AM | 1 Like Like |Link to Comment
  • AF Backtracking, AMRN Will Be Approved On Time [View instapost]
    I find it irrational that the FDA would make it a condition that AMRN conduct a hugely expensive outcomes trial, and then cut off the company from the means of support to finish that trial.

    Given the excellent safety signals of EPA, and with the only long term trial of an EPA-only drug returning positive results, along with the fact that drugs failing an outcomes are still on market and widely used, I hope that FDA is indeed rational.

    It will be interesting to see if anyone on the committee has an agenda, or worse conflicted interests, to taint the logic. When you say "the panel agree[s] that waiting for CVOT data before expanding Vascepa's label is the correct action to take" it shows the difference between a 'journalist' and a reporter. A bias, and a seemingly bitter one at that, having seen the derision you save for AMRN and it's stockholders. I hope no one you care about would be required to wait 2 more years, they may not have, to see if taking a clean profile drug is any good for them. Not to mention , although not robust, the additional data from all those regular patients would help settle the questions.

    Let physicians and patients decide if they have time to fritter around a few years.
    Sep 25 10:18 PM | 5 Likes Like |Link to Comment
  • Vascepa Scripts Keep Screaming For Amarin [View article]
    See US National Library of Medicine, National Institutes of Health

    http://1.usa.gov/16v2J4k

    Conclusion
    Dyerberg and colleagues examined the relationship between EPA and CVD, and the JELIS study recently demonstrated that EPA administration reduces the risk of CVD. An important difference between EPA and DHA is the metabolism of EPA to bioactive PGI3. It is assumed that, similar to PGI2, PGI3 inhibits platelet aggregation, vascular contrac- tion, myocardial ischemic injury and arteriosclerosis and induces neoangiogenesis. Therefore, it is specu- lated that the CVD risk reduction induced by EPA is also associated with the effects of PGI3 in addition to the numerous effects of EPA itself (such as TG reduc- tion, inflammation inhibition and improvements in plasma membrane fluidity). This hypothesis is con- firmed by the following findings: an increased CVD risk was found to be associated with a reduction in the EPA/AA ratio, and the EPA/AA ratio was found to be positively correlated with the (PGI2+PGI3)/TXA2 ratio.
    Sep 24 12:43 AM | 2 Likes Like |Link to Comment
  • Vascepa Scripts Keep Screaming For Amarin [View article]
    Eicosapentaenoic Acid (EPA) Reduces Cardiovascular Events: Relationship with the EPA/Arachidonic Acid Ratio.

    soon to be published in the J Atheroscler. Thromb. 2013 Sep 18.
    pre publ. softcopy; http://bit.ly/16v2J4m

    Abstract
    The clinical efficacy of fish oil and high-purity eicosapentaenoic acid ethyl ester (hp-EPA-E) for treat- ing cardiovascular disease (CVD) has been reported. Fish oil contains saturated and monounsatu- rated fatty acids that have pharmacological effects opposite to those of ω3 fatty acids (ω3). Moreover, ω3, such as EPA and docosahexaenoic acid (DHA), do not necessarily have the same metabolic and biological actions. This has obscured the clinical efficacy of ω3. Recently, the Japan EPA Lipid Inter- vention Study (JELIS) of hp-EPA-E established the clinical efficacy of EPA for CVD, and higher lev- els of blood EPA, not DHA, were found to be associated with a lower incidence of major coronary events. A significant reduction in the risk of coronary events was observed when the ratio of EPA to arachidonic acid (AA) (EPA/AA) was >0.75. Furthermore, the ratio of prostaglandin (PG) I3 and PGI2 to thromboxane A2 (TXA2) ([PGI2+PGI3]/TXA2) was determined to have a linear relationship with the EPA/AA ratio as follows: (PGI2+PGI3)/TXA2 =λ+π* (EPA/AA). Like PGI2, PGI3 not only inhib- its platelet aggregation and vasoconstriction, but also is assumed to reduce cardiac ischemic injury and arteriosclerosis and promote angiogenesis. Thus, the effects of EPA in reducing the risk of CVD could be mediated by biological action of PGI3 in addition to hypotriglyceridemic action of EPA. Compared with DHA, EPA administration increases the EPA/AA ratio and the (PGI2+PGI3)/TXA2 balance to a state that inhibits the onset and/or progression of CVD.
    Sep 24 12:37 AM | 1 Like Like |Link to Comment
  • Explosive Bidding Situation Setting Up For Amarin [View instapost]
    I, for one, am overjoyed if we are witnessing the Death of the Run Up.
    Here's little hint ; when 'everybody' knows a secret ... it aint!. A couple years bio was dead, then the Run Up became the norm. My guess is that rug is being pulled.

    Like the housing bubble when people who didn't know which end of a hammer to hit or hold, but they were going to flip them a couple houses, jacking up prices on crummy shacks till the Wiley-Coyote-over-the-... moment that we all pay for to today.

    I watched one of the twitter gods clean & jerk ACAD a couple times for a couple dimes. Everyone praised the smart man. Actually he was leading 1000s into the name then dumping all over on his own sheep for relative peanuts. Yet I notice that conviction buyers, studying then suffering all that stress & derision before data, and under $2, are doing quite nicely today (I am talking to me here.)

    Of course I am worried too, but its about high time for a sea change, at least for awhile, where you have to do the DD, survey the sources, then white knuckle down and trust your own thoughts, rather than try to step off the train at a precise moment before the station ... walking over a bunch of other people's backs in the process.

    Maybe I'm a dreamer ... but I'm not the only one who happens to think the markets are intended to capitalize the development of good ideas and great products in capable hands, and not serve as coin dispenser for a mass of weak conviction players.
    Sep 23 12:30 PM | Likes Like |Link to Comment
  • The Captain Of Amarin's Listless Ship Makes Ready For The Storm [View article]
    oh yeah I forgot Scry; mega kudos on your CYCC call, I was reminded of the name by your article the other day but omitted getting back in it in time . Congrats and great fortune to you.
    Sep 20 05:19 PM | 1 Like Like |Link to Comment
COMMENTS STATS
66 Comments
60 Likes